Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study

Florentino, Pilar T. V; Millington, Tristan; Silva, Thiago Cerqueira; Robertson, Chris; Oliveira, Vinicius de Araújo; Júnior, Juracy B S; Alves, Flávia J O; Penna, Gerson O; Katikireddi, Srinivasa Vital; Boaventura, Viviane S; Werneck, Guilherme L; Pearce, Neil; McCowan, Colin; Sullivan, Christopher; Agrawal, Utkarsh; Grange, Zoe; Ritchie, Lewis D; Simpson, Colin R; Sheikh, Aziz; Barreto, Mauricio L; Rudan, Igor; Barral Netto, Manoel; Paixão, Enny S

Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study

Detalhes bibliográficos
Autor(a) principal:	Florentino, Pilar T. V
Data de Publicação:	2022
Outros Autores:	Millington, Tristan, Silva, Thiago Cerqueira, Robertson, Chris, Oliveira, Vinicius de Araújo, Júnior, Juracy B S, Alves, Flávia J O, Penna, Gerson O, Katikireddi, Srinivasa Vital, Boaventura, Viviane S, Werneck, Guilherme L, Pearce, Neil, McCowan, Colin, Sullivan, Christopher, Agrawal, Utkarsh, Grange, Zoe, Ritchie, Lewis D, Simpson, Colin R, Sheikh, Aziz, Barreto, Mauricio L, Rudan, Igor, Barral Netto, Manoel, Paixão, Enny S
Tipo de documento:	Artigo
Idioma:	eng
Título da fonte:	Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo:	https://www.arca.fiocruz.br/handle/icict/55114
Resumo:	Research and Innovation (Medical Research Council). Scottish Government. Health Data Research UK. BREATHE Hub, Fiocruz. Fazer o Bem Faz Bem programme. Brazilian National Research Council. Wellcome Trust.

Metadados do item

id	CRUZ_66faffb0ca477f271ed5cdc6e973e1f5
oai_identifier_str	oai:www.arca.fiocruz.br:icict/55114
network_acronym_str	CRUZ
network_name_str	Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str	2135
spelling	Florentino, Pilar T. VMillington, TristanSilva, Thiago CerqueiraRobertson, ChrisOliveira, Vinicius de AraújoJúnior, Juracy B SAlves, Flávia J OPenna, Gerson OKatikireddi, Srinivasa VitalBoaventura, Viviane SWerneck, Guilherme LPearce, NeilMcCowan, ColinSullivan, ChristopherAgrawal, UtkarshGrange, ZoeRitchie, Lewis DSimpson, Colin RSheikh, AzizBarreto, Mauricio LRudan, IgorBarral Netto, ManoelPaixão, Enny S2022-10-11T18:33:55Z2022-10-11T18:33:55Z2022FLORENTINO, Pilar T. V et al. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. The Lancet Infectious Diseases, p. 1-10, 2022.1474-4457https://www.arca.fiocruz.br/handle/icict/5511410.1016/S1473-3099(22)00451-0Research and Innovation (Medical Research Council). Scottish Government. Health Data Research UK. BREATHE Hub, Fiocruz. Fazer o Bem Faz Bem programme. Brazilian National Research Council. Wellcome Trust.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos em Saúde. Salvador, BA, Brasil / Universidade de São Paulo. Instituto de Ciências Biomédicas. São Paulo, Brasil.University of Edinburgh. Usher Institute. Edinburgh, UK.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratórios LIB e LEITV. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Instituto de Saúde Coletiva. Salvador, BA, Brasil.Public Health Scotland. Glasgow, Scotland, UK.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos em Saúde. Salvador, BA, Brasil.Universidade Federal da Bahia. Faculdade de Medicina. Instituto de Saúde Coletiva. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos em Saúde. Salvador, BA, Brasil.Universidade de Brasília. Centro de Medicina Tropical. Escola de Governo da Fiocruz Brasília. Brasília, DF, BrasilUniversity of Glasgow. MRC/CSO Social and Public Health Sciences Unit. Glasgow, UK.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratórios LIB e LEITV. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Instituto de Saúde Coletiva. Salvador, BA, Brasil.Universidade do Estado do Rio de Janeiro. Instituto de Medicina Social. Departamento de Epidemiologia. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Instituto de Estudos de Saúde Coletiva. Rio de Janeiro, RJ, Brasil.Faculty of Epidemiology and Population Health. London School of Hygiene & Tropical Medicine. London, UK.University of St Andrews. School of Medicine St Andrews. Scotland, UK.Public Health Scotland Glasgow. Scotland, UK.University of St Andrews. School of Medicine St Andrews. Scotland, UK.Public Health Scotland Glasgow. Scotland, UK.University of Aberdeen. Academic Primary Care. Aberdeen, Scotland, UK.Victoria University of Wellington. Wellington Faculty of Health. School of Health. Wellington, New Zealand.University of Edinburgh. Usher Institute. Edinburgh, UK.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos em Saúde. Salvador, BA, Brasil.University of Edinburgh. Usher Institute. Edinburgh, UK.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos em Saúde. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratórios LIB e LEITV. Salvador, BA, Brasil.Faculty of Epidemiology and Population Health. London School of Hygiene & Tropical Medicine. London, UK.Background: Little is known about vaccine effectiveness over time among adolescents, especially against the SARS-CoV-2 omicron (B.1.1.529) variant. This study assessed the associations between time since two-dose vaccination with BNT162b2 and the occurrence of symptomatic SARS-CoV-2 infection and severe COVID-19 among adolescents in Brazil and Scotland. Methods: We did test-negative, case-control studies in adolescents aged 12–17 years with COVID-19-related symptoms in Brazil and Scotland. We linked records of SARS-CoV-2 RT-PCR and antigen tests to national vaccination and clinical records. We excluded tests from individuals who did not have symptoms, were vaccinated before the start of the national vaccination programme, received vaccines other than BNT162b2 or a SARS-CoV-2 booster dose of any kind, or had an interval between their first and second dose of fewer than 21 days. Additionally, we excluded negative SARS-CoV-2 tests recorded within 14 days of a previous negative test, negative tests recorded within 7 days after a positive test, any test done within 90 days after a positive test, and tests with missing sex and location information. Cases (SARS-CoV-2 test-positive adolescents) and controls (test-negative adolescents) were drawn from a sample of individuals in whom tests were collected within 10 days of symptom onset. We estimated the adjusted odds ratio and vaccine effectiveness against symptomatic COVID-19 for both countries and against severe COVID-19 (hospitalisation or death) for Brazil across fortnightly periods. Findings: We analysed 503 776 tests from 2 948 538 adolescents in Brazil between Sept 2, 2021, and April 19, 2022, and 127 168 tests from 404 673 adolescents in Scotland between Aug 6, 2021, and April 19, 2022. Vaccine effectiveness peaked at 14–27 days after the second dose in both countries during both waves, and was significantly lower against symptomatic infection during the omicron-dominant period in Brazil (64·7% [95% CI 63·0–66·3]) and in Scotland (82·6% [80·6–84·5]), than it was in the delta-dominant period (80·7% [95% CI 77·8–83·3] in Brazil and 92·8% [85·7–96·4] in Scotland). Vaccine efficacy started to decline from 27 days after the second dose for both countries, reducing to 5·9% (95% CI 2·2–9·4) in Brazil and 50·6% (42·7–57·4) in Scotland at 98 days or more during the omicron-dominant period. In Brazil, protection against severe disease remained above 80% from 28 days after the second dose and was 82·7% (95% CI 68·8–90·4) at 98 days or more after receiving the second dose. Interpretation: We found waning vaccine protection of BNT162b2 against symptomatic COVID-19 infection among adolescents in Brazil and Scotland from 27 days after the second dose. However, protection against severe COVID-19 outcomes remained high at 98 days or more after the second dose in the omicron-dominant period. Booster doses for adolescents need to be considered.engElsevierSARS-CoV-2COVID-19Infecção graveAdolescentesVacinaçãoSARS-CoV-2COVID-19Infection severeAdolescentsVaccinationVaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/55114/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALFlorentino, Pilar - Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19.pdfFlorentino, Pilar - Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19.pdfapplication/pdf507390https://www.arca.fiocruz.br/bitstream/icict/55114/2/Florentino%2c%20Pilar%20-%20Vaccine%20effectiveness%20of%20two-dose%20BNT162b2%20against%20symptomatic%20and%20severe%20COVID-19.pdf2f05b3e7373794f90d6ab244785748ecMD52icict/551142023-03-15 14:32:49.0oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:32:49Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.en_US.fl_str_mv	Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
title	Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
spellingShingle	Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study Florentino, Pilar T. V SARS-CoV-2 COVID-19 Infecção grave Adolescentes Vacinação SARS-CoV-2 COVID-19 Infection severe Adolescents Vaccination
title_short	Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
title_full	Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
title_fullStr	Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
title_full_unstemmed	Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
title_sort	Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
author	Florentino, Pilar T. V
author_facet	Florentino, Pilar T. V Millington, Tristan Silva, Thiago Cerqueira Robertson, Chris Oliveira, Vinicius de Araújo Júnior, Juracy B S Alves, Flávia J O Penna, Gerson O Katikireddi, Srinivasa Vital Boaventura, Viviane S Werneck, Guilherme L Pearce, Neil McCowan, Colin Sullivan, Christopher Agrawal, Utkarsh Grange, Zoe Ritchie, Lewis D Simpson, Colin R Sheikh, Aziz Barreto, Mauricio L Rudan, Igor Barral Netto, Manoel Paixão, Enny S
author_role	author
author2	Millington, Tristan Silva, Thiago Cerqueira Robertson, Chris Oliveira, Vinicius de Araújo Júnior, Juracy B S Alves, Flávia J O Penna, Gerson O Katikireddi, Srinivasa Vital Boaventura, Viviane S Werneck, Guilherme L Pearce, Neil McCowan, Colin Sullivan, Christopher Agrawal, Utkarsh Grange, Zoe Ritchie, Lewis D Simpson, Colin R Sheikh, Aziz Barreto, Mauricio L Rudan, Igor Barral Netto, Manoel Paixão, Enny S
author2_role	author author author author author author author author author author author author author author author author author author author author author author
dc.contributor.author.fl_str_mv	Florentino, Pilar T. V Millington, Tristan Silva, Thiago Cerqueira Robertson, Chris Oliveira, Vinicius de Araújo Júnior, Juracy B S Alves, Flávia J O Penna, Gerson O Katikireddi, Srinivasa Vital Boaventura, Viviane S Werneck, Guilherme L Pearce, Neil McCowan, Colin Sullivan, Christopher Agrawal, Utkarsh Grange, Zoe Ritchie, Lewis D Simpson, Colin R Sheikh, Aziz Barreto, Mauricio L Rudan, Igor Barral Netto, Manoel Paixão, Enny S
dc.subject.other.en_US.fl_str_mv	SARS-CoV-2 COVID-19 Infecção grave Adolescentes Vacinação
topic	SARS-CoV-2 COVID-19 Infecção grave Adolescentes Vacinação SARS-CoV-2 COVID-19 Infection severe Adolescents Vaccination
dc.subject.en.en_US.fl_str_mv	SARS-CoV-2 COVID-19 Infection severe Adolescents Vaccination
description	Research and Innovation (Medical Research Council). Scottish Government. Health Data Research UK. BREATHE Hub, Fiocruz. Fazer o Bem Faz Bem programme. Brazilian National Research Council. Wellcome Trust.
publishDate	2022
dc.date.accessioned.fl_str_mv	2022-10-11T18:33:55Z
dc.date.available.fl_str_mv	2022-10-11T18:33:55Z
dc.date.issued.fl_str_mv	2022
dc.type.status.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv	info:eu-repo/semantics/article
format	article
status_str	publishedVersion
dc.identifier.citation.fl_str_mv	FLORENTINO, Pilar T. V et al. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. The Lancet Infectious Diseases, p. 1-10, 2022.
dc.identifier.uri.fl_str_mv	https://www.arca.fiocruz.br/handle/icict/55114
dc.identifier.issn.en_US.fl_str_mv	1474-4457
dc.identifier.doi.none.fl_str_mv	10.1016/S1473-3099(22)00451-0
identifier_str_mv	FLORENTINO, Pilar T. V et al. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. The Lancet Infectious Diseases, p. 1-10, 2022. 1474-4457 10.1016/S1473-3099(22)00451-0
url	https://www.arca.fiocruz.br/handle/icict/55114
dc.language.iso.fl_str_mv	eng
language	eng
dc.rights.driver.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	Elsevier
publisher.none.fl_str_mv	Elsevier
dc.source.none.fl_str_mv	reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ
instname_str	Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str	FIOCRUZ
institution	FIOCRUZ
reponame_str	Repositório Institucional da FIOCRUZ (ARCA)
collection	Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv	https://www.arca.fiocruz.br/bitstream/icict/55114/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/55114/2/Florentino%2c%20Pilar%20-%20Vaccine%20effectiveness%20of%20two-dose%20BNT162b2%20against%20symptomatic%20and%20severe%20COVID-19.pdf
bitstream.checksum.fl_str_mv	5a560609d32a3863062d77ff32785d58 2f05b3e7373794f90d6ab244785748ec
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5
repository.name.fl_str_mv	Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv	repositorio.arca@fiocruz.br
_version_	1798324809280520192

Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study

Registros relacionados